Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TransMedics Group Inc (TMDX) vs T Rowe Price Group Inc (TROW) Price & Performance

TransMedics Group IncTrade
T Rowe Price Group IncTrade

Price performance (Past 24H)

Key statistics

TransMedics Group Inc vs T Rowe Price Group Inc — how do they compare? TransMedics Group Inc trades at $87.31 (market cap $3.10B), while T Rowe Price Group Inc trades at $111.17 (market cap $24.26B). The key difference: T Rowe Price Group Inc is far larger — about 7.8× TransMedics Group Inc's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

TMDXTROW
Market Cap
$3.10B$24.26B
Sector
TechnologyFinancials
52-Week High
$150.42$121.68
52-Week Low
$61.99$86.19
Enterprise Value
$3.49B$21.46B
Dividend Yield
4.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.

T Rowe Price Group Inc

T. Rowe Price (TROW) trades at $111.17, down 2.29% on the day, with a bearish technical signal driven by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $2.57, supported by record assets under management. Revenue and net income have shown steady growth, with 2025 revenue at $7.31B and net income at $2.09B. The company maintains strong profitability, with a net margin of 29.26% and ROE of 20.1%. Valuation ratios appear reasonable, with a P/E of 11.42 and EV/EBITDA of 6.75. Dividends remain consistent, with a recent quarterly payment of $1.30 declared.

The outlook for TROW is mixed; fundamental strength from earnings growth and solid cash flow supports potential upside, but technical bearishness and analyst caution pose near-term risks. Investment opportunity lies in its undervalued metrics and dividend reliability, while risks include expense pressures and market volatility affecting asset flows. The consensus price target of $112.17 suggests limited upside from current levels, emphasizing a hold stance amid balanced factors.

Returns comparison

Trailing returns across standard periods

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX

About T Rowe Price Group Inc

T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.

Read more on TROW